Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in this application.

1. (currently amended) A chimeric, humanized or human antibody that ~~competitively~~ inhibits binding of an amphiregulin polypeptide to an epidermal growth factor receptor ~~anti-amphiregulin antibody~~, wherein the amphiregulin polypeptide consists ~~essentially~~ of SEQ ID NO: 1, and wherein the ~~anti-amphiregulin~~ antibody comprises ~~a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 12 and a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 5 and 14.~~ a heavy chain variable region defined by SEQ ID NO: 2 and a light chain variable region defined by SEQ ID NO: 3; a heavy chain variable region defined by SEQ ID NO: 4 and a light chain variable region defined by SEQ ID NO: 5; or a heavy chain variable region defined by SEQ ID NO: 12 and a light chain variable region defined by SEQ ID NO: 14.

2. (cancelled)

3. (currently amended) The antibody of claim 1, wherein the ~~anti-amphiregulin~~ antibody ~~is selected from the group consisting of: an antibody comprising SEQ ID NO: 2 and SEQ ID NO: 3; an antibody comprising SEQ ID NO: 4 and SEQ ID NO: 5; and an antibody comprising SEQ ID NO: 12 and SEQ ID NO: 14.~~ comprises a heavy chain variable region defined by SEQ ID NO: 2 and a light chain variable region defined by SEQ ID NO: 3.

4. (currently amended) The antibody of claim 1, wherein the antibody comprises ~~SEQ ID NO: 12 and SEQ ID NO: 14.~~ a heavy chain variable region defined by SEQ ID NO: 12 and a light chain variable region defined by SEQ ID NO: 14.

5. (original) The antibody of claim 1, wherein the antibody is an antibody fragment.

6. (original) The antibody of claim 5, wherein the antibody fragment is selected from the group consisting of Fab, Fab', $F(ab')_2$, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.

7. (original) The antibody of claim 1, wherein the antibody is conjugated to an effector moiety.

8. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a cancer cell.

9. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a skin cell.

10. (cancelled)

11. (cancelled)

12. (cancelled)

13. (original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 1.

14. (original) The pharmaceutical composition of claim 13, wherein the antibody is conjugated to an effector moiety.

15. (original) The pharmaceutical composition of claim 13, wherein the antibody comprises SEQ ID NO: 12 and SEQ ID NO: 14.

16. (cancelled)

17. (cancelled)

18. (currently amended) The antibody of claim 1, wherein the antibody comprises a heavy chain variable region defined by SEQ ID NO: 4 and a light chain variable region defined by SEQ ID NO: 5. ~~A chimeric, humanized or human antibody that specifically binds to an amphiregulin polypeptide, wherein the amphiregulin polypeptide consists essentially of SEQ ID NO: 1, and wherein the antibody binds to the same amphiregulin epitope as that bound by an antibody selected from the group consisting of: an antibody comprising a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 3; an antibody comprising a heavy chain variable region of SEQ ID NO: 4 and a light chain~~

~~variable region of SEQ ID NO: 5; and an antibody comprising a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.~~

19. (cancelled)

20. (cancelled)

21. (currently amended) The antibody of claim 1 ~~18~~, wherein the antibody inhibits proliferation of tumor cells.

22. (currently amended) The antibody of claim 1 ~~18~~, wherein the antibody inhibits *in vivo* proliferation of tumor cells that express amphiregulin.

23. (currently amended) The antibody of claim 1 ~~18~~, wherein the antibody neutralizes at least one biological activity of amphiregulin.

24. (currently amended) The antibody of claim 1 ~~18~~, wherein the antibody is conjugated to an effector moiety.

25. (currently amended) The antibody of claim 1 ~~18~~, wherein the antibody competes for binding to the ligand binding site of a ligand of amphiregulin.

26. (cancelled)

27. (cancelled)

28. (currently amended) A hybridoma producing the antibody of claim 1 ~~18~~.

29. (cancelled)

30. (cancelled)

31. (cancelled)

32. (currently amended) ~~A~~ An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 12 and 14.

33. (cancelled)

34. (cancelled)

35. (cancelled)

36. (cancelled)

37. (cancelled)

38. (cancelled)

39. (cancelled)

40. (cancelled)

41. (cancelled)

42. (cancelled)

43. (cancelled)

44. (cancelled)

45. (cancelled)

46. (cancelled)

47. (currently amended) ~~The~~ A chimeric, humanized or human antibody ~~of claim 46, wherein the antibody comprises~~ comprising a heavy chain variable region defined by ~~of~~ SEQ ID NO: 2 and a light chain variable region defined by ~~of~~ SEQ ID NO: 3.

48. (currently amended) ~~The~~ A chimeric, humanized or human antibody ~~of claim 46, wherein the antibody comprises~~ comprising a heavy chain variable region defined by ~~of~~ SEQ ID NO: 4 and a light chain variable region defined by ~~of~~ SEQ ID NO: 5.

49. (currently amended) ~~The~~ A chimeric, humanized or human antibody ~~of claim 46, wherein the antibody comprises~~ comprising a heavy chain variable region defined by ~~of~~ SEQ ID NO: 12 and a light chain variable region defined by ~~of~~ SEQ ID NO: 14.

50. (new) The antibody of claim 49, wherein the antibody is an antigen binding fragment that is selected from the group consisting of Fab, Fab', $F(ab')_2$, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.

51. (new) The antibody of claim 49, wherein the antibody is conjugated to an effector moiety.

52. (new) A pharmaceutical composition comprising the antibody of claim 49 and a pharmaceutically acceptable excipient.